title: Total joint replacement in haemophilia A patients with high titre of inhibitor using a new brand recombinant factor VIIa (Aryoseven(®) ).
authors.affiliation: Joint Reconstruction Research Center, Tehran University of Medical Sciences, Tehran, Iran. smjmort@yahoo.com.
authors.forename: S M J
authors.initials: SM
authors.lastname: Mortazavi
authors.affiliation: Joint Reconstruction Research Center, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: A
authors.initials: A
authors.lastname: Najafi
authors.affiliation: Thrombosis Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: G
authors.initials: G
authors.lastname: Toogeh
mesh_terms: D000328:Adult; D019643:Arthroplasty, Replacement; D003362:Cost-Benefit Analysis; D015942:Factor VIIa / Q000191:economics / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy / Q000191:economics / Q000601:surgery*; D006801:Humans; D008297:Male; D011788:Quality of Life; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D011994:Recombinant Proteins; D015942:Factor VIIa